RT Book, Section
A1 Cain, Hilary C.
A2 Grippi, Michael A.
A2 Elias, Jack A.
A2 Fishman, Jay A.
A2 Kotloff, Robert M.
A2 Pack, Allan I.
A2 Senior, Robert M.
A2 Siegel, Mark D.
SR Print(0)
ID 1122361853
T1 Drug-Induced Pulmonary Disease Due to Nonchemotherapeutic Agents
T2 Fishman's Pulmonary Diseases and Disorders, 5e
YR 2015
FD 2015
PB McGraw-Hill Education
PP New York, NY
SN 978-0-07-179672-9
LK accessmedicine.mhmedical.com/content.aspx?aid=1122361853
RD 2024/04/24
AB Drugs  have  long  been  recognized  as  having  the  potential  to  cause  pulmonary  injury.  The  precise  incidence  of  drug-induced  lung  disease  is  difficult  to  ascertain,  because  the  signs  and  symptoms  of  disease  are  shared  by  many  other  pulmonary  conditions  and  diseases.  An  analysis  of  a  database  of  approximately  9  million  patients  from  the  United  Kingdom  describes  an  incidence  density  of  0.7  per  100,0000  patient  years  for  interstitial  disease  related  to  drugs  over  a  12-year  period  (1997–2008).1  These  data  reflect  only  a  portion  of  the  impact  of  drug-induced  respiratory  disease,  because  the  alveoli,  upper  and  lower  airways,  pleura,  pulmonary  vasculature,  muscles  of  respiration,  and  the  central  nervous  system  governing  respiratory  control  are  all  susceptible  to  injury  from  ingested,  inhaled,  and  parenterally  administered  agents.  As  the  categories  and  varieties  of  therapeutic  drugs  continue  to  increase,  clinicians  will  encounter  disease  from  new  culprit  drugs  in  addition  to  well-established  drug  reactions.  Web-based  data  repositories,  such  as  www.pneumotox.com,  can  serve  as  useful  tools  for  the  clinician,  as  they  provide  frequent  updates  based  on  the  emerging  literature  on  drug  toxicities.